Home-based Longitudinal Investigation of the Multidisciplinary Team Integrated Care (HOLISTIC)
29. januar 2020 opdateret af: Chao A. Hsiung, National Health Research Institutes, Taiwan
Developing Innovative Models for Health & Long-term Care Facilities and Technology Services: Prospective Cohort Study for Home Health Care
Some research found the effectiveness of implementation of home health care on patients' physical function, quality of life (QoL) and decreased the risk of hospitalization and medical costs.
However, little was known about the longitudinal change of comprehensive assessments of physical and mental health, QoL, well-being, and medical resource utilization of patients receiving home health care and their caregivers.
Furthermore, the evaluation of advance care planning, palliative care need, and the quality of dying and death were also insufficient among the aforementioned population.
Therefore, this cohort study aims to investigate the longitudinal change of health-related outcomes and utilization of resource utilization, and explore their trajectories in two years for patients who receive home health care and their caregivers in Taiwan.
Studieoversigt
Status
Ukendt
Betingelser
Detaljeret beskrivelse
This is a prospective longitudinal cohort study in Taiwan. Data will be collected by trained interviewers at the baseline (T0), 3-month follow-up (T1), 6-month follow-up (T2), 12-month follow-up (T3), 18-month follow-up (T4), and 24-month follow-up (T5). Via home visits, interviewer-administered questionnaires (informed consent, contact/follow-up information, background information, health condition, physical functioning, cognitive function, etc.) will be used. It estimates that the home visit will take up to 2 hours.
The investigators will recruit at least 1200 eligible patients and caregivers (600 dyads) from at least 15 institutions (e.g., home clinics and hospitals) which provide home health care. Trained research assistants will touch based with eligible participants recommended by institution staff and invite them to take part in the study. To ensure the study are achieving the target sample the investigators will examine the distribution of living area and number of participants in each type of home health care unit during recruiting. Moreover, the investigators have estimated an attrition rate of 20% over the study. Higher drop-off rates in certain sub-groups may be problematic, so the investigators will monitor participants' attrition.
In addition, the cohort the investigators enrolled will be linked to their data in Taiwan's National Health Insurance Research Database to analyze the medical resource utilization of participants in our study. The results will show the health status and resource utilization as well as quality of home health care in Taiwan for clinical practices, research and future policy making.
Undersøgelsestype
Observationel
Tilmelding (Forventet)
1200
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Miaoli County
-
Zhunan, Miaoli County, Taiwan, 35053
- Chao A. Hsiung
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
20 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
patients with home health care and their caregivers
Beskrivelse
Inclusion Criteria:
- Aged 20 years or older
- Receiving home health care services at least two months
- Either the patient or caregiver can express clearly
Exclusion Criteria:
- Reject to sign the informed consent
- Both the patient and caregiver cannot complete the interview
- Both the patient and caregiver cannot communicate with an interviewer in a familiar language
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
patient
patients who receive home health care
|
|
caregiver
caregivers who take care of patients with home health care
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from ability to perform activities of daily living (ADL) at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
The Barthel Index will be adapted to assess ADL.
The total score ranges from 0 to 100, with 100 indicating full independence in doing daily activities.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from frailty at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the 9-point Clinical Frailty Scale (CFS).
The total score ranges from 1 to 9, with 7 or higher indicating severe frailty, even being terminally ill.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from cognitive function/memory at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the Brain Health Test (Chinese version) via testing the orientation to time, immediate and delayed recall of five items, categorical verbal fluency test.
The total score ranges from 0 to 16, with higher scores indicating worse cognitive impairment.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from percentage of participants with Dementia at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
The Functional Assessment Staging Test (FAST) will be adapted to assess an individual's stage of Alzheimer's disease.
It includes seven stages from normal aging to sever Dementia.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from mean score of depression at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the 5-item Geriatric Depression Scale (GDS).
The total score ranges from 0 to 5, with higher scores indicating more depression.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from neuropsychiatric status at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the Neuropsychiatric Inventory.
The 10 sub-domains of behavioral functioning are examined, including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity syndrome.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from quality of life (QOL) at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
We will adapt the Quality of Life in Alzheimer's Disease (QOL-AD) scale for patients with cognitive impairment, and Quality of Life Survey for Home Care (QOL-HC) scale for those without cognitive impairment.
The total score of QOL-AD ranges from 13 to 52, with higher values indicating a higher QoL.
The total score of QOL-HC ranges from 0 to 8, with higher values indicating a higher QoL.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from mental wellbeing at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the World Health Organization- Five Well-Being Index (WHO-5).
The raw score ranges from 0 to 25, 0 representing worst possible and 25 representing best possible quality of life.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Shared decision making (SDM)
Tidsramme: Two years
|
It will be measured by the Decision-making Participation Self-Efficacy Scale (DEPS).
The total score ranges from 5 to 25, with higher scores indicating higher self-efficacy.
|
Two years
|
|
Advance Care Planning (ACP)
Tidsramme: Two years
|
It will be measured by the 4-question version of UCSF-ACP with the Process Measures (knowledge, contemplation, self-efficacy, and readiness, 5-point Likert scales) and Action Measures (yes/no whether an ACP behavior is completed).
|
Two years
|
|
Change from Nutrition status at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will include the Mini Nutritional Assessment (MNA).
The total score of MNA ranges from 0-14, with more than 11 indicating normal nutrition status.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from risk for pressure injury at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the sale of Braden Scale for Predicting Pressure Sore Risk.
The scale is composed of six subscales that reflect sensory perception, skin moisture, activity, mobility, friction and shear, and nutritional status.
The total score ranges from 6 to 23, with higher scores indicating lower risk for forming pressure sores.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Needs assessment for supportive & palliative care
Tidsramme: Two years
|
It will be measured by the Supportive & Palliative Care Indicators Tool (SPICT).
Following the guideline, the Chinese version will be developed before the cohort study starts.
|
Two years
|
|
Change from medical resource utilization at two years
Tidsramme: Baseline, 3-month follow-up, 12-month follow-up, 24-month follow-up
|
Assessments include medical costs and out-of-pocket costs regarding utilization of medical resource and home health care.
The used scales are developed by our research team.
|
Baseline, 3-month follow-up, 12-month follow-up, 24-month follow-up
|
|
Change from caregiving burden at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by the revised version of Zarit Burden interview containing 22 items, with higher scores indicating greater burden.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
|
Change from number of used chronic disease drug at two years
Tidsramme: Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
It will be measured by two items which are developed by our research team.
Based on patients' prescriptions, they will be required to answer the number of chronic disease drug they used and these drugs' information, including the names, administrations and dosages.
|
Baseline, 3-month follow-up, 6-month follow-up, 12-month follow-up, 18-month follow-up, 24-month follow-up
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Studieleder: Chao A. Hsiung, PhD, National Health Research Institutes, Taiwan
- Ledende efterforsker: Sang-Ju Yu, MD, Taiwan Society of Home Health Care and Home Clinic Dulan
- Ledende efterforsker: Ping-Jen Chen, MD, Kaohsiung Medical University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
20. november 2019
Primær færdiggørelse (Faktiske)
20. november 2019
Studieafslutning (Forventet)
31. december 2022
Datoer for studieregistrering
Først indsendt
15. januar 2020
Først indsendt, der opfyldte QC-kriterier
29. januar 2020
Først opslået (Faktiske)
31. januar 2020
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
31. januar 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
29. januar 2020
Sidst verificeret
1. januar 2020
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EC1080203
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .